All stem cells-be they pluripotent embryonic stem (ES) cells, multipotent tissue-specific stem cells, or cancer stem cells-have both the capacity to self-renew and to differentiate into many different mature cell types. Sustaining homeostatic control in normal tissues is achieved by the ability of resident stem cells to balance these two processes to ensure that mature cells are generated throughout life without depletion of stem cell reserves. Understanding how stem cells and their microenvironments regulate these processes has clinical implications because loss of homeostatic control is a defining characteristic of heritable and acquired degenerative conditions, aging, and malignant transformation.
Cancers of diverse tissues may originate from and be maintained by minor subpopulations of cells within the tumor called cancer stem cells (CSCs) (Bonnet and Dick, 1997; AlHajj et al., 2003; Singh et al., 2004) . It was Dick's group who identified in patients with acute myelogenous leukemia (AML) a small subset of CSCs (termed leukemia-initiating cells) that caused disease when transplanted into mice with severe combined immunodeficiency (Bonnet and Dick, 1997) . These leukemia-initiating cells shared many markers with normal hematopoietic stem cells (HSCs) and exhibited extensive proliferative and selfrenewal potential.
Given that CSCs share many functional properties with normal stem cells, including the potential for unlimited self-renewal, and that many of the critical pathways involved in maintaining normal stem cell function are also deregulated in cancer, therapies directed against CSCs targeting such shared pathways might also inadvertently decimate normal resident stem cells. A study by Yilmaz et al. (2006) in Nature now identifies different selfrenewal mechanisms for maintaining pools of leukemic stem cells and normal HSCs. The authors show that deletion of the Pten tumor suppressor gene results in generation of leukemic stem cells but depletion of normal HSCs. This mechanistic distinction may enable the design of therapies to combat leukemia that target the PTEN pathway with the goal of killing leukemic stem cells without damaging the normal stem cell pool.
In our view, the genetic and epigenetic events leading to progression of hematopoietic cells to leukemia must occur in self-renewing cells, or else must impart non-selfrenewing cells with self-renewal capability, with each event marking a more malignant subset, yet leaving behind the less malignant clone (Reya et al., 2001; Weissman, 2005) .
Normally, the genetically regulated pathways that enable the transition from self-renewing stem cells to non self-renewing progenitor cells ensure that self-renewal is shut off as differentiation proceeds. Failure to shut off the self-renewal pathways could confer self-renewal on cells and microenvironments capable of evading homeostatic regulation. The extent to which CSCs are derived directly from transformed stem cells, or are the result of transformative events that impart stem cell-like properties onto more committed progenitors, is only just beginning to be elucidated and is likely to vary depending on the type of cancer. However, significant deregulation of the mechanisms governing normal self-renewal is implied because this process is usually tightly regulated.
Normal tissue stem cells and CSCs share many phenotypic and functional properties in addition to self-renewal capacity. For example, stem cells express high levels of many ABC/MDR transporter genes (Rossi et al., 2005; Zhou et al., 2001) , which mediate drug efflux. Indeed, the ability of AML cells to pump out chemotherapeutic agents enables them to evade the destructive effects of these drugs and contributes to relapse in leukemia patients (Wulf et al., 2001 ). In fact, the leading cause of death in cancer Self-renewal pathways crucial for maintaining stem cells are deregulated in cancer, raising the spectre that cancer therapies targeting such pathways might also ablate normal stem cells. As Yilmaz et al. (2006) report in a recent Nature paper, this may not be the case for the tumor suppressor protein Pten, which drives the self-renewal of normal hematopoietic stem cells and the formation of leukemia cells through different mechanisms.
patients continues to be the intrinsic or acquired resistance of tumor cells to chemotherapeutics. Another property of HSCs likely to be shared by their leukemic progeny is the constant movement of these cells out of bone marrow into blood to seed distant marrow and extramedullary hematopoietic sites (Wright et al., 2001) . Such a capability may explain why myelogenous leukemias are never local but are found throughout the bone marrow.
These observations have led to studies of the pathways by which normal and neoplastic stem cells self-renew and differentiate. Many pathways known to promote tumorigenesis-such as the Wnt, Notch, and sonic hedgehog signaling pathways-have been implicated in stem cell self-renewal (Reya et al., 2001) . Similarly, proteins such as p16 and p19 that suppress tumorigenesis also inhibit stem cell self-renewal (Molofsky et al., 2005) . The overexpression or absence of genes, such as bmi1, that regulate these proteins has been implicated in leukemogenesis (Lessard and Sauvageau, 2003) . The fact that so many pathways critical to tumorigenesis are so intimately linked to normal stem cell self-renewal raises the spectre that cancer therapies targeting such pathways might ablate resident stem cells.
Enter Yilmaz and colleagues (2006) with their study of the Pten tumor suppressor protein and its role in normal HSCs and in leukemic transformation. They inactivated Pten in the murine hematopoietic system using a flox-Cre system (a flox Pten allele in Mx-1-Cre mice). Loss of Pten in these Pten fl/fl Mx-1-Cre mice quickly led to a myeloproliferative disease that progressed rapidly to frank leukemia, including AML and ALL. Several hematopoietic populations from the Pten fl/fl Mx-1-Cre mice caused leukemia when transplanted into irradiated recipients, but it was the HSC population that was most enriched for leukemia-initiating cells.
The investigators report that deletion of the Pten gene resulted in HSCs being driven rapidly into the cell cycle. This led to transient increases in HSC numbers but with time resulted in depletion of HSC reserves in the mouse bone marrow. Pten-deficient HSCs, when transplanted into irradiated mice, were only capable of short-term multilineage reconstitution of the hematopoietic system and could not stably engraft irradiated recipients long-term. Indeed, the Pten-deficient HSCs could not maintain their numbers even in wild-type recipient mice, demonstrating that the deficit was intrinsic to these cells. The authors found no evidence for increased apoptosis underlying the depletion of Pten-deficient HSC reserves. Taken together, these experiments argue that Pten normally maintains HSCs in a quiescent state; in the absence of Pten, HSCs are driven into the cell cycle, eventually leading to depletion of HSC reserves. One possible explanation for these events is the unexpected quantitative failure of HSCs during the active phases of the cell cycle to home to bone marrow when placed in the bloodstream (although homing to extramedullary hematopoietic sites was not affected) (Fleming et al., 1993) . Loss of Pten may force HSCs out of quiescence resulting in depletion of the bone marrow HSC pool and the accumulation of HSCs in extramedullary hematopoietic sites that cannot sustain HSC self-renewal. Crucially, the impact of Pten loss on HSC selfrenewal is independent of the role that Pten inactivation plays in driving leukemogenesis. Thus, two distinct Pten-based mechanisms drive HSC self-renewal and the genesis of leukemia-initiating cells.
The lipid kinase phosphoinositide 3-kinase (PI3K) is activated in response to a variety of extracellular signals, generating 3′ phosphoinositide lipids. These lipids are intracellular secondary messengers and elicit diverse cellular responses (including proliferation, survival, and cell growth) by acting upon downstream targets such as Akt kinase and the mTOR signaling pathway. The PTEN tumor suppressor protein is believed to be the central lipid phosphatase attenuating PI3K signaling, and loss of PTEN promotes the formation of a variety of tumors. Deregulation of the mTOR signaling pathway is a prominent consequence of PTEN inactivation. This pathway may be an attractive therapeutic target for treating tumors carrying inactivated PTEN because mTOR activity can be suppressed by a number of compounds including rapamycin.
To attempt to therapeutically exploit the mechanistic distinction between Pten's activity in stem cell self-renewal and leukemogenesis, Yilmaz et al. administered rapamycin to the Pten fl/fl Mx-1-Cre mice. In contrast to control animals, which all quickly developed leukemia, the Pten-deficient mice treated with rapamycin did not. This finding demonstrates that rapamycin can block the generation or maintenance of leukemia-initiating cells. Importantly, rapamycin treatment was effective in reducing the frequency of leukemiainitiating cells even when treatment was initiated after the onset of frank leukemia.
The impact of rapamycin treatment on the HSC compartment of Pten fl/fl Mx-1-Cre mice was equally impressive. The capacity of HSCs from rapamycin-treated Pten fl/fl Mx-1-Cre mice to reconstitute the hematopoietic system of irradiated recipient mice was restored, and their cell-cycle distribution was normalized. Rapamycin treatment also eliminated the transient expansion of HSCs in Pten fl/fl Mx-1-Cre mice and prevented depletion of the marrow HSC pool, demonstrating that the normal self-renewal capacity of HSCs had been restored.
The Yilmaz et al. study provides key insights into the mechanistic heart of both normal stem cells and CSCs. The cancer stem cell model of tumorigenesis predicts that for cancer therapies to be clinically effective over the long-term, they must target the small subset of CSCs that is responsible for maintaining and spreading the tumor. Drugs that target self-renewal potential would seem to be attractive candidate can-cer therapies except for the fact that such strategies also might unintentionally eliminate normal bystander stem cells that use self-renewal as part of their regular functional repertoire. The elegant work of Yilmaz and coworkers, however, demonstrates that it is possible to identify and therapeutically target pathways that differentially impact the selfrenewal of normal and CSCs within the same tissue. As suggested by this study, genes that promote stem cell quiescence might be particularly amenable to such targeted strategies because although normal stem cells thrive in a quiescent world, forcing CSCs to adopt quiescence could spell their defeat.
